Immuno-Oncology | Specialty

Ongoing Clinical Trials in Second-Line HCC

September 8th 2017

Second-Line HCC: Unmet Needs

September 8th 2017

HCC: Evolution of Frontline Treatment

September 8th 2017

Frontline Lenvatinib in HCC: Study 304

September 8th 2017

Unmet Needs in Systemic Therapy for Liver Cancer

September 8th 2017

Initial Treatment Decisions in Liver Cancer

September 8th 2017

Evidence With SIRT in HCC

September 8th 2017

Role of TACE in Liver Cancer

September 8th 2017

Radiofrequency Ablation Vs Resection in HCC

September 8th 2017

HCC and Liver Transplantation

September 8th 2017

Liver Cancer Screening Strategies

September 8th 2017

Comorbidities and Management of HCC

September 8th 2017

Importance of Multidisciplinary Care in Liver Cancer

September 8th 2017

Dr. Gandara Discusses PD-L1 as a Biomarker in Lung Cancer

September 8th 2017

David R. Gandara, MD, director, Thoracic Oncology Program, professor, senior advisor to director, UC Davis Comprehensive Cancer Center, treasurer, International Association for the Study of Lung Cancer, discusses PD-L1 as a biomarker in lung cancer.

Dr. Hammers on Immunotherapy Combinations in Kidney Cancer

September 8th 2017

Hans J. Hammers, MD, PhD, associate professor, Internal Medicine, UT Southwestern Medical Center, discusses combinations with immunotherapy being investigated for patients with kidney cancer.

Dr. Usmani on Potential of Checkpoint Inhibitors in Multiple Myeloma

September 7th 2017

Saad Z. Usmani, MD, Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute/Carolinas HealthCare System, discusses the potential of checkpoint inhibitors as monotherapy and in combination.

FDA Halts Enrollment on 3 Nivolumab Myeloma Trials

September 7th 2017

The FDA has placed partial clinical holds on 3 trials assessing nivolumab (Opdivo)-based combinations in patients with relapsed/refractory multiple myeloma.

Update Confirms Benefit of Pembrolizumab Plus Indoximod in Melanoma

September 7th 2017

Adding the IDO inhibitor indoximod to pembrolizumab (Keytruda) led to an overall response rate of 61% in patients with advanced melanoma.

Dr. Bunn on the Response of Immunotherapy in Lung Cancer

September 7th 2017

Paul A. Bunn Jr, MD, distinguished professor, Division of Medical Oncology/University of Colorado, James Dudley Chair in Lung Cancer Research, University of Colorado Denver, 2014 Giant of Cancer Care in Lung Cancer, discusses the response of immunotherapy in patients with lung cancer.

Pembrolizumab Approved in Europe for Urothelial Carcinoma

September 6th 2017

The European Commission has approved pembrolizumab (Keytruda) for the treatment of patients with locally advanced or metastatic urothelial carcinoma who have received prior platinum-containing chemotherapy, or who are not eligible for cisplatin-containing chemotherapy.